EULAR DO NOT MISS

➢ Oral presentations and posters
➢ Mentor/Mentee Meetings
➢ Country Liaison Meeting
➢ EMEUNET Sessions
➢ EULAR/EMEUNET Interest Groups
➢ EMEUNET Research Speed Dating
➢ Educational Opportunities
Dear young rheumatologists and researchers,

We are delighted to present to you a new issue of EMEUNews, focusing on a selection of abstracts, sessions and events not to be missed at the EULAR 2022 Congress.

After two year of break, this year EULAR will be held both online and in person. The pandemics provided the advantage of digital format, as the sessions may be accessed from anywhere at any time, but this year it is thrilling to have the opportunity to meet and greet colleagues in person. The scientific program is as lively as you expect it to be for the central event of the year. In this newsletter, we provide you with a selection of oral presentations and posters, thoughtfully picked by our contributors, that we consider being noteworthy. The most interesting abstracts for each section (in our opinion) are selected. Although the abstracts represent a personal and inevitably limited selection from the vast amount of information to be presented, we believe that our selections will provide some inspiration to attendees.

In addition, this Newsletter contains details about EMEUNET events organized during the event. As always, EMEUNET will be active on social media including Facebook and Twitter during the Congress.

We wish you a prolific and successful EULAR 2022 Congress. Looking forward to meeting you in Copenhagen!

Gizem Ayan, Diego Benavent and Mikhail Protopopov, on behalf of the EMEUNET Newsletter Sub-Committee

More information about EMEUNET can be found at http://emeunet.eular.org

www.facebook.com/EMEUNET
www.twitter.com/EMEUNET
https://www.linkedin.com
EMEUNET Tube
EMEUNET Podcast
Aggelos Banos

Aggelos is a rheumatology resident physician and a junior researcher at Biomedical Research Foundation of the Academy of Athens. His major research interests include SLE and vasculitides (clinical aspects, outcomes, genetics, molecular taxonomy). Aggelos is a member of the Country Liaison Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0138</td>
<td>Friday, 03.06.2022 12.10 – 12.18</td>
<td>Biomarkers in pathogenesis, monitoring and treatment of rheumatic diseases</td>
<td>Prediletto E. (UK)</td>
<td>RHEUMATOID SYNOVIAL FIBROBLASTS DISPLAY IMPRINTED MEMORY OF THEIR SYNOVIAL ENDOTYPE WHICH CAN BE PLASTICALLY MODULATED BY B-CELLS CROSSTALK</td>
</tr>
<tr>
<td>Poster 0326</td>
<td>Saturday, 04.06.2022 10:17 - 10:25</td>
<td>New data on pathophysiology of spondyloarthritides including psoriatic arthritis</td>
<td>Grivas A. (Greece)</td>
<td>THE TRANSCRIPTOMIC LANDSCAPE OF ACTIVE PSPORTIAC ARTHRITIS: ACTIVATED INNATE IMMUNITY, EXTRACELLULAR MATRIX (ECM) TURNOVER, ABERRANT METABOLISM AND HEMOPOIETIC CELL - SKIN CROSSTALK</td>
</tr>
<tr>
<td>Poster 0039</td>
<td>Thursday, 02.06.2022 13.06 – 13.14</td>
<td>Genomics, functional genomics and genetic basis of inflammatory arthritis</td>
<td>Woodridge L. (United Kingdom)</td>
<td>MONOCYTE TRANSCRIPTOMICS AND TARGETED PROTEOMICS DEFINE HETEROGENEOUS SUBGROUPS IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND SUBCLINICAL ATHEROSCLEROSIS</td>
</tr>
<tr>
<td>Oral 0102</td>
<td>Thursday, 02.06.2022 10.55 – 11.05</td>
<td>Exploring the origin of inflammation in spondyloarthritis</td>
<td>Micheroli R. (Switzerland)</td>
<td>THE SYNOVIUM IN CHRONIC INFLAMMATORY JOINT DISEASES: COMPARISON OF CLINICAL, HISTOLOGICAL AND scRNA-SEQ Data BETWEEN RA, PsA, SpA AND UA</td>
</tr>
<tr>
<td>Oral 0110</td>
<td>Thursday, 02.06.2022 10.45 – 10.55</td>
<td>From gene to function: genetic basis of rheumatic diseases</td>
<td>Nakano M. (Japan)</td>
<td>CELL-TYPE-SPECIFIC TRANSCRIPTOME ARCHITECTURE UNDERLYING THE ESTABLISHMENT AND EXACERBATION OF SYSTEMIC LUPUS ERYTHEMATOSUS</td>
</tr>
<tr>
<td>Poster 0142</td>
<td>Friday, 03.06.2022 12.42 – 12.50</td>
<td>Biomarkers in pathogenesis, monitoring and treatment of rheumatic diseases</td>
<td>Zahid Siddiqi K. (Denmark)</td>
<td>DISTINCT EXPRESSION CLUSTERS OF INTERFERON-REGULATED GENES ASSOCIATE DIFFERENTLY WITH DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS</td>
</tr>
</tbody>
</table>

In essence, this study stresses a recent need for re-endotyping diseases through cell types, as well as depicts the crosstalk of synovial fibroblasts and B-cells in RA.

Thorough description of the cross-talk of key effector cell of psoriatic arthritis, through high-throughput techniques.

Monocytic characteristics are mapped through transcriptomics and proteomics, towards explaining immune state, metabolism and atherosclerosis.

Synovium study of various autoimmune entities is exploiting multiple layers of both clinical and molecular information.

A complex prototype disease such as SLE, explained through the lens of the dense transcriptional network of various cell types.

Interferon signalling in SLE is substantial for the course of the disease and this study enlightens the differential profile of IRGs, combined with clinical data.
Elise is a postdoc researcher at the department of Rheumatology of both the LUMC, Leiden and the Erasmus MC, Rotterdam, the Netherlands. Her research focus is on the very early detection of rheumatoid arthritis and on tapering treatment in RA seen from a clinical, patient, and societal perspective. Elise is a member of the Education subcommittee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>0032 Wednesday 01 June 2022 16:35 - 16:45</td>
<td>From risk assessment to societal outcomes</td>
<td>S Pazmino (Belgium)</td>
<td>AN ECONOMIC WINDOW OF OPPORTUNITY FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: 5-YEAR COST-EFFECTIVENESS ANALYSIS OF THE CARERA TRIAL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>This research shows longer term cost-effectiveness (5 years) of treat to target treatment in early RA, and points out an economic window of opportunity to lower costs, but maintaining good disease control.</td>
</tr>
<tr>
<td>Oral</td>
<td>0290 Friday 03 June 2022 11:05 - 11:15</td>
<td>The early bird gets the worm</td>
<td>B van Dijk (Netherlands)</td>
<td>WHICH INFLAMED TISSUES EXPLAIN A POSITIVE SQUEEZE TEST OF THE METATARSOPHALANGEAL JOINTS? A LARGE IMAGING STUDY TO INCREASE UNDERSTANDING OF A COMMONLY PERFORMED DIAGNOSTIC PROCEDURE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A positive squeeze test of the feet can be explained by intra- and juxta articular inflamed tissue detected with MRI.</td>
</tr>
<tr>
<td>Poster</td>
<td>0504 Wednesday 01 June 2022 09:28 - 09:36</td>
<td>Rheumatoid arthritis - prognosis, predictors and outcome</td>
<td>J Gwinnut (UK)</td>
<td>LOW SOCIAL SUPPORT, WORSE FINANCIAL STATUS AND LIMITED PHYSICAL ACTIVITY AT RHEUMATOID ARTHRITIS ONSET PREDICTS EXCESS DISABILITY OVER 10 YEARS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Excess disability in RA may partly be explained by lack of social support, financial instability and lower physical fitness at symptom onset.</td>
</tr>
<tr>
<td>Poster</td>
<td>0608 Wednesday 01 June 2022 10:00 - 10:08</td>
<td>Rheumatoid arthritis - comorbidity and clinical aspects</td>
<td>L De Stefano (Italy)</td>
<td>PROGRESSIVE INCREASE IN THE DIAGNOSTIC DELAY AND PERSISTENTLY SEVERE CLINICAL PRESENTATION OVER THE YEARS IN AUTOANTIBODY NEGATIVE PATIENTS WITH RHEUMATOID ARTHRITIS IN THE SETTING OF AN EARLY ARTHRITIS CLINIC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A large proportion of RA still has diagnostic delay, especially seen within autoantibody negative RA patients.</td>
</tr>
<tr>
<td>Oral</td>
<td>0006 Wednesday 01 June 2022 15:20 - 15:30</td>
<td>Is gender sufficiently studied in RMDs?</td>
<td>J Sigaux (France)</td>
<td>CLEANING ACTIVITIES, DUSTY CLOTHES LAUNDRY AND TALCUM HANDLING ARE UNDERESTIMATED MAJOR SOURCES OF EXPOSURE TO CRYSTALLINE SILICA IN WOMEN WITH RHEUMATOID ARTHRITIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Inhalation of crystalline silica is associated with RA development, though exposure is previously only measured within male workers, while women could also be exposed.</td>
</tr>
<tr>
<td>Poster</td>
<td>0587 Wednesday 01 June 2022 20:16 - 20:24</td>
<td>Rheumatoid arthritis - comorbidity and clinical aspects</td>
<td>B Squercioni (France)</td>
<td>TRAJECTORIES AND FACTORS INFLUENCING THE EVOLUTION OF HAND GRIP AMONG PATIENTS WITH RHEUMATOID ARTHRITIS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>The majority of RA patients show improvement of hand grip over time (2 years), though very few normalized their hand grip.</td>
</tr>
</tbody>
</table>
RA II – CLINICAL (THERAPEUTIC)

Lise Verhoef

* Lise is a postdoctoral researcher at the Department of Rheumatology of the Sint Maartenskliniek, Nijmegen, the Netherlands. Her major research interest are rheumatoid arthritis and bDMARDs, patient-centered treatment strategies and e-health. She is a Member of the Peer Mentoring Subgroup.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 0061</td>
<td>Wednesday, 01.06.2022 17.05 – 17.15</td>
<td>Modern biological treatment in RA</td>
<td>Luppino, A (Italy)</td>
<td>TIGHT CONTROL IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TARGETED THERAPIES ACROSS THE COVID-19 PANDEMIC ERA</td>
</tr>
<tr>
<td>Oral 0070</td>
<td>Wednesday, 01.06.2022 17.15 – 17.25</td>
<td>Plenary Abstract Session</td>
<td>Krijbolder, D (Netherlands)</td>
<td>INTERVENTION WITH METHOTREXATE IN ARTHRALGIA AT RISK FOR RHEUMATOID ARTHRITIS TO REDUCE THE DEVELOPMENT OF PERSISTENT ARTHRITIS AND ITS DISEASE BURDEN (TREAT EARLIER): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL</td>
</tr>
<tr>
<td>Oral 0118-HPR</td>
<td>Thursday 02.06.2022 10.55 – 11.05</td>
<td>HPR: From prevention to management</td>
<td>Poulis, B (Netherlands)</td>
<td>GAMING FOR ADHERENCE TO MEDICATION USING E-HEALTH IN RHEUMATOID ARTHRITIS (GAMER) STUDY – A RANDOMISED CLINICAL TRIAL</td>
</tr>
<tr>
<td>Oral 0263</td>
<td>Friday, 03.06.2022 10.35-10.45</td>
<td>RA treatment: modern strategies and new molecules</td>
<td>Boers, M (Netherlands)</td>
<td>FAVORABLE BALANCE OF BENEFIT AND HARM OF LONG-TERM, LOW-DOSE PREDNISOLONE ADDED TO STANDARD TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS AGED 65+: THE PRAGMATIC, MULTICENTER, PLACEBO-CONTROLLED GLORIA TRIAL</td>
</tr>
<tr>
<td>Oral 0266</td>
<td>Friday, 03.06.2022 11.05-11.15</td>
<td>RA treatment: modern strategies and new molecules</td>
<td>Nham, E (Switzerland)</td>
<td>TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS AS AN OVERALL MEASURE OF TOLERANCE AND SAFETY OF JAK-INHIBITORS: AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-pot” STUDY).</td>
</tr>
<tr>
<td>Poster 0286</td>
<td>Saturday 04.06.2022 10.17 – 10.25</td>
<td>All you want to know about bDMARDs in RA.</td>
<td>Meng, C (USA)</td>
<td>CAN PATIENTS WITH CONTROLLED RA RECEIVING ANY CLASS OF TARGETED THERAPY WITH METHOTREXATE (MTX) SUSTAIN DISEASE CONTROL AFTER TAPERING MTX? A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
</tr>
</tbody>
</table>

Although the pandemic has imposed changes in our healthcare delivery, different strategies regarding face-to-face and virtual visits seem to be effective in ensuring satisfactory management of RA treated with targeted therapies.

MTX initiated at the pre-arthritis stage of joint symptoms and subclinical inflammation did not prevent the development of clinical arthritis but did seem to modify the disease course.

This RCT showed that a serious puzzle game aimed at reinforcing a positive attitude towards DMARDs was frequently played but did not improve medication adherence, beliefs about medication or clinical outcomes in RA patients.

Add-on low dose prednisolone has beneficial long-term effects on disease activity and damage progression in senior RA patients on standard treatment.

After adjusting for potential confounders, the rate of treatment discontinuation for adverse events was comparable between JAKi and bDMARDs with other modes of action or TNFi.

Patients with controlled RA have a high probability of maintaining disease control after tapering their methotrexate to targeted therapy alone, up to 18 months.
Diego is a consultant rheumatologist at Hospital Universitario La Paz in Madrid, where he is doing his PhD on axial spondyloarthritis. He also collaborates as medical expert in Savana, a medical company working on artificial intelligence in medicine. Diego is a member of the Newsletter Sub-Committee.

**SPONDYLOARTHRITIS I - NON-THERAPEUTIC**

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster</td>
<td>0956</td>
<td>Wednesday, 01.06.2022 16.24 – 16.32</td>
<td>Spondyloarthritis - clinical aspects (other than treatment)</td>
<td>Shi, J.L.H. (China)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster</td>
<td>0964</td>
<td>Wednesday, 01.06.2022 17.28 – 17.36</td>
<td>Spondyloarthritis - clinical aspects (other than treatment)</td>
<td>Marques, ML (Portugal)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster</td>
<td>0970</td>
<td>Wednesday, 01.06.2022 18.16 – 18.24</td>
<td>Spondyloarthritis - clinical aspects (other than treatment)</td>
<td>Rios Rodríguez, V (Germany)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster</td>
<td>0307</td>
<td>Saturday, 04.06.2022 10.17 – 10.25</td>
<td>Clinical aspects in Psoriatic Arthritis</td>
<td>Zhao, S.S (UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>0148</td>
<td>Thursday 02.06.2022 10:35 - 10:45</td>
<td>Spondyloarthritis in practice: imaging, outcome assessment and comorbidities</td>
<td>Navarro-Compán, V (Spain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>0126</td>
<td>Thursday 02.06.2022 11.05 – 11.15</td>
<td>Pregnancy outcomes in rheumatic diseases</td>
<td>Morin, M (Sweden)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Krystel is a rheumatologist at the Department of Rheumatology, Saint George hospital, Beirut, Lebanon. She completed her MPH degree in Research and Biostatistics at Paris-Saclay university, France. Her major research interests include spondyloarthritis and psoriatic arthritis (clinical aspects, imaging, outcomes and treatments). Krystel is a member of the Visibility and Global Affairs Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 0016</td>
<td>Wednesday, 01.06.2022 16:35 - 16:45</td>
<td>AxSpA drug treatment: new and old drugs</td>
<td>Van den Bosch, F. (Belgium)</td>
<td>EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL</td>
</tr>
</tbody>
</table>

These results support the potential use of upadacitinib in patients with active nr-axSpA. Upadacitinib 15 mg QD demonstrated significantly greater improvements in disease activity, pain, function, quality of life, and MRI-detected SI joint inflammation than placebo after 14 wks of treatment in pts with active nr-axSpA.

| Oral 0019 | Wednesday, 01.06.2022 17:05 – 17:15 | AxSpA drug treatment: new and old drugs | Van der Heijde D. (Netherlands) | BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO- CONTROLLED STUDY |

Dual inhibition of IL-17A and IL-17F with bimekizumab in patients with active AS resulted in rapid, clinically relevant improvements in efficacy outcomes vs placebo. No new safety signals were observed.

| Oral 0020 | Wednesday, 01.06.2022 17:15 - 17:25 | AxSpA drug treatment: new and old drugs | Hellamand, P. (Netherlands) | SEX DIFFERENCES IN EFFECTIVENESS OF FIRST-LINE TUMOR NECROSIS FACTOR INHIBITORS IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM FIFTEEN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION NETWORK |

Treatment efficacy and retention rates are lower among female patients with axSpA initiating their first TNFi. Females presented with lower CRP levels and higher scores on patient reported outcomes at baseline, reflecting differences in disease expression.

| Oral 0021 | Wednesday, 01.06.2022 17:25 - 17:35 | AxSpA drug treatment: new and old drugs | Torgutalp, M. (Germany) | TREATMENT WITH NON-STEROIDAL ANTIINFLAMMATORY DRUGS IS ASSOCIATED WITH RETARDATION OF RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 10-YEAR RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT |

Higher NSAID intake is associated with lower radiographic spinal progression, particularly in r-axSpA patients. COX2i might possess a stronger inhibitory effect on radiographic progression as compared to NS-NSAIDs.

| Oral 0261 | Friday, 03.06.2022 11:35 - 11:45 AM | Emerging treatment strategies in PsA | Michielsens, C. (Netherlands) | TREAT-TO-TARGET DOSE REDUCTION AND WITHDRAWAL STRATEGY OF TNF INHIBITORS IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED NON-INFERIORITY TRIAL |

A treat-to-target (T2T) TNFi tapering strategy is non-inferior to a T2T strategy without tapering with regard to the proportion of patients still in low disease activity at 12 months and results in a substantial reduction of TNFi use, albeit with slightly more use of other medication.
Mariana, MD, PhD student, is a rheumatologist and clinical researcher at the Rheumatology Department, Centro Hospitalar e Universitário de Coimbra and Universidade de Coimbra in Portugal. Her research focuses on the origin of fibromyalgia based on a biopsychosocial model. She is a member of the Social Media Subgroup.

### Poster 1105

**Wednesday 01.06.22 09:36-09:44**  
**Poster View 8**  
A. Singh (Australia)  
**Efficacy and Safety of Colchicine for the Treatment of Osteoarthritis: A Systematic Review and Meta-Analysis of Intervention Trials**

This abstract shows no conclusive benefit of colchicine in pain or physical function in hand/knee OA patients.

### Poster 1115

**Wednesday 01.06.22 10:56-11:04**  
**Poster View 8**  
T. Delgado (France)  
**Efficacy and Safety of the Combination of PRP + Non-Crosslinked Hyaluronic Acid versus Hyaluronic Acid, in Mono-Injection, in Symptomatic Knee Osteoarthritis. Randomized Controlled Phase III Trial, Single Blind**

This abstract shows the combination of PRP-non-crosslinked HA in mono-injection was at least equivalent to Hylan-G-F 20 for symptomatic benefit (WOMAC) at 6 months, with a good safety profile.

### Poster 1146

**Wednesday 01.06.22 15:04-15:12**  
**Poster View 8**  
S. Anno (Japan)  
**Romosozumab Increase Bone Mineral Density at Lumbar and Femoral Irrespective of Preosteoporosis Treatment, History of Fragility Fracture and Combination of Vitamin D**

This abstract shows Romosozumab improved BMD at lumbar and femoral independently regardless of preosteoporosis treatment, history of fragility fracture and combination of vitamin D.

### Oral 0243

**Friday 03.06.22 11:05-11:15**  
**Osteoporosis**  
K. Poole (UK)  
**Osteoporosis Case-Finding in People Undergoing Routine Diagnostic CT Scans Almost Tripled the Rate of Osteoporosis Treatment at 12 Months. A Randomised, Multi-Centre Feasibility Study Using Waiting Room FRAX, Opportunistic CT Bone Density and Vertebral Fracture Assessment versus Usual Care**

This abstract shows osteoporosis treatment rates were almost tripled by screening patients attending for routine diagnostic CT scans with waiting room FRAX, CT-bone densitometry and vertebral fracture analysis.

### Oral 0240

**Friday 03.06.22 10:45-10:55**  
**Osteoporosis**  
C. Amigues (France)  
**Zoledronate-Related Osteonecrosis of the Jaw in Osteoporosis: Incidence, Risk Factors and Comparison to Oral Bisphosphonates**

This abstract shows the risk of incidence of osteonecrosis of the jaw on zoledronate by rheumatological indication is higher than on alendronate or risedronate, suggesting a risk associated with the inhibitory power of bone resorption.
Cristiana is a rheumatology fellow at Complejo Asistencial Universitario de León (Spain). Her major interests are systemic lupus erythematosus and systemic sclerosis. She is also interested in translational research, clinical immunology, and musculoskeletal epidemiology. Cristiana is a member of the Social Media Subcommittee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 0285</td>
<td>Wednesday 01.06.2022 16:00</td>
<td>Recent novelties in SLE/Sjogren and APS?</td>
<td>H. J. Anders (Germany)</td>
<td>VOCLOSPORIN IS EFFECTIVE IN ACHIEVING PROTEINURIA TREATMENT TARGETS IN LUPUS NEPHRITIS DEFINED BY EULAR/ERA RECOMMENDATIONS</td>
</tr>
<tr>
<td>Oral 0147</td>
<td>Thursday 02.16.2022 11:35</td>
<td>Remission, flares and predictive factors in SLE, Sjogren and anti-phospholipid syndrome</td>
<td>Diogo Jesus (Portugal)</td>
<td>THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS</td>
</tr>
<tr>
<td>Poster 0721</td>
<td>Thursday 02.06.22 12:45</td>
<td>SLE, Sjögren’s and APS – treatment</td>
<td>Daniele Lini (Italy)</td>
<td>ASSOCIATION BETWEEN PRECONCEPTION COMPLEMENT LEVELS AND USE OF HYDROXYCHLOROQUINE WITH PREGNANCY OUTCOME IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME AND CARRIERS OF ANTIPHOSPHOLIPID ANTIBODIES: AN INTERNATIONAL MULTICENTER STUDY</td>
</tr>
<tr>
<td>Poster 0741</td>
<td>Thursday 02.06.22 12:45</td>
<td>SLE, Sjögren’s and APS - clinical aspects (other than treatment)</td>
<td>Silvia G. Foddai (Italy)</td>
<td>REPORT FROM THE APS STUDY GROUP OF THE ITALIAN SOCIETY FOR RHEUMATOLOGY (SIR-APS) ON APL NEGATIVIZATION</td>
</tr>
<tr>
<td>Oral 0231</td>
<td>Friday 03.06.2022 10:35</td>
<td>Novel etiopathogenic aspects in SLE and Sjögren’s syndrome</td>
<td>P. Rybakowska (Spain)</td>
<td>MASS CYTOMETRY DATA RECLASSIFY SYSTEMIC AUTOIMMUNE DISEASE PATIENTS IN PHENOTYPICALLY DISTINCTIVE GROUPS</td>
</tr>
<tr>
<td>Oral 0237</td>
<td>Friday 03.06.2022 11:15</td>
<td>Novel etiopathogenic aspects in SLE and Sjögren’s syndrome</td>
<td>M. Shipa (UK)</td>
<td>DISTINCT IMMUNE NETWORKS STRATIFY ORGAN INVOLVEMENT AND RESPONSE TO B CELL TARGETED THERAPIES IN SYSTEMIC LUPUS ERYTHEMATOSUS</td>
</tr>
</tbody>
</table>

This abstract explores differences and similarities between systemic autoimmune diseases using high-dimensional cytometry data for determining cell frequencies and expression levels of functional markers.

This abstract identifies biomarkers of clinical response to belimumab after rituximab in the BEAT-lupus trial defined as reduction to BILAG C in all domains.
Mikhail is a rheumatologist and a junior researcher at the Department of Gastroenterology, Infectiology and Rheumatology, Charité University, Berlin, Germany. His major research interests include spondyloarthritis and psoriatic arthritis (clinical aspects, imaging, epidemiology and outcomes). Mikhail is the Leader of the Newsletter Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster</td>
<td>Wednesday, 01.06.2022 17.12 – 17.20</td>
<td>Crystal diseases, metabolic bone diseases other than osteoporosis</td>
<td>Lamoreaux, B (USA)</td>
<td>PREVALENCE AND IMPACT OF DERMATOLOGIC CONDITIONS IN PATIENTS WITH GOUT</td>
</tr>
<tr>
<td>Poster</td>
<td>Wednesday, 01.06.2022 18.32 – 18.40</td>
<td>Crystal diseases, metabolic bone diseases other than osteoporosis</td>
<td>Cipolletta, E (Italy)</td>
<td>RISK OF VENOUS THROMBOEMBOLISM AFTER GOUT FLARES</td>
</tr>
<tr>
<td>Oral</td>
<td>Thursday 02.06.2022 10.55 – 11.05</td>
<td>Translational and Clinical Research in Crystal Arthritis</td>
<td>Cipolletta, E (Italy)</td>
<td>ULTRASONOGRAPHY IN THE PREDICTION OF GOUT FLARES: A 12-MONTH PROSPECTIVE OBSERVATIONAL STUDY</td>
</tr>
<tr>
<td>Oral</td>
<td>Thursday 02.06.2022 11.05 – 11.15</td>
<td>Translational and Clinical Research in Crystal Arthritis</td>
<td>Sirotti, S, Italy)</td>
<td>DEVELOPMENT OF AN ULTRASOUND SCORING SYSTEM FOR CPPD EXTENT: RESULTS FROM A DELPHI PROCESS AND WEB-RELIABILITY EXERCISE BY THE OMERACT US WORKING GROUP</td>
</tr>
<tr>
<td>Oral</td>
<td>Thursday 02.06.2022 11.35 – 11.45</td>
<td>Translational and Clinical Research in Crystal Arthritis</td>
<td>Botson, J (USA)</td>
<td>A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER, STUDY OF METHOTREXATE COMBINED WITH PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT</td>
</tr>
<tr>
<td>Poster</td>
<td>Saturday 04.06.2022 11.05 – 11.13</td>
<td>Advances in Crystal Arthritis</td>
<td>Shin, A (South Korea)</td>
<td>UPDATE ON COMPARATIVE CARDIOVASCULAR SAFETY OF FEBUXOSTAT VERSUS ALLOPURINOL AMONG PATIENTS WITH GOUT</td>
</tr>
</tbody>
</table>

In a large claims-based study, dermatologic conditions were known in 29% of gout patients. Those with dermatologic conditions had higher comorbidity burden than those without. The study showed transitory increase in the venous thromboembolism risk after gout flares. Finding monosodium urate deposits and signs of subclinical inflammation by sonography was able to predict gout flares over 12 months. The first scoring system for determining the extent of calcium pyrophosphate crystal deposition in patients with calcium pyrophosphate deposition disease. Combination of pegloticase and methotrexate was associated with a higher rate of sustained urate-lowering response over 6 months as compared to pegloticase alone. In contrast to previous studies, a similar cardiovascular safety profile was shown in febuxostat and allopurinol-treated patients with gout, with all-cause mortality reduced by 16% in febuxostat group users compared to allopurinol.
• Ertugrul has recently completed his post-doc in Vasculitis Translational Research Program at National Institutes of Health (NIH). He is currently focusing on translational research about vasculitides and rare rheumatic diseases in Turkey. Ertugrul is a member of the Peer-Mentoring Subcommittee.

**OTHER CONNECTIVE TISSUE DISEASES AND VASCULITIS**

Ertugrul C. Bolek

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0901</td>
<td>Wednesday, 01.06.2022, 09.04-09.12</td>
<td>Sclerodermia, myositis and related syndromes</td>
<td>Martinho J. (Portugal)</td>
<td>INTERSTITIAL LUNG DISEASE IN MIXED CONNECTIVE TISSUE DISEASE: CLINICAL AND SEROLOGICAL ASSOCIATIONS</td>
</tr>
</tbody>
</table>

Older age at diagnosis and lymphadenopathy at disease onset were found as independent predictors of ILD in a cohort of 57 patients with Mixed Connective Tissue Disease.

| Oral 0091 | Wednesday, 01.06.2022, 16.45-16.55 | The Yin and Yang of scleroderma and vasculitis | Scherer H. U (Netherlands) | EXPANSION OF MYELOPEROXIDASE (MPO)-SPECIFIC IgM B CELLS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS |

MPO-specific, IgM-expressing memory B cells may provide novel insights in pathophysiology of ANCA-Associated Vasculitis (AAV) through complement pathway.

| Oral 0092 | Wednesday, 01.06.2022, 16.55-17.05 | The Yin and Yang of scleroderma and vasculitis | Elhai M. (Switzerland) | DECIPHERING THE SYNOVIAL TISSUE AND FIBROBLAST SUBSETS IN SYSTEMIC SCLEROSIS |

This study emphasized the low inflammatory nature of the synovium and increased TGF-β and interferon signaling SSc synovial fluid. The data can be important to rethink on novel specific therapeutic targets for SSc in comparison with RA.

| Oral 0180 | Thursday, 02.06.2022, 10.35-10.45 | Vessels glowing in the dark | Merkel P.A, (USA) | EFFECT OF AVACOPAN ON RELAPSE RATES AND RELAPSE-FREE TIME IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS, RESULTS OF THE PHASE 3 ADVOCATE STUDY |

Relapse Rates And Relapse-free Time were also significantly higher in AAV patients under treatment of Avacopan compared to prednisone group.

| Oral 0236 | Friday, 03.06.2022, 11.05-11.15 | Novel etiopathogenic aspects in SLE and Sjögren’s syndrome | Colafrancesco, S (Italy) | JAK-STAT INHIBITION RESTORES EPITHELIAL CELLS’ HOMEOSTASIS IN PRIMARY SJÖGREN’S SYNDROME |

Baricitinib and other JAKinibs can be promising novel therapies for pSS through reduced autophagy and countered the state of maladaptive activation of salivary gland epithelial cells.

| Poster 0274 | Saturday, 04.06.2022, 11.37-11.45 | Achy-Breaky vessels | Dai, X. (China) | PREDICTION OF VASCULAR COMPLICATIONS IN TAKAYASU ARTERITIS BY MACHINE LEARNING: A PROOF-OF-CONCEPT STUDY BASED ON A PROSPECTIVE COHORT |

Machine learning algorithms can predict vascular complications in Takayasu arteritis. Progressive clinical course was an important clue for all models.
Mert is a consultant rheumatologist in Istanbul Research and Training Hospital. His main interests are autoinflammatory disorders and large vessel vasculitis. Mert is a member of the Peer Mentoring Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 0042</td>
<td>Wednesday 01.06.2022 16.35-16.45</td>
<td>Infection-related and other orphan rheumatic disorders</td>
<td>Henes, J (Germany)</td>
<td>LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY</td>
</tr>
<tr>
<td>Oral 0066</td>
<td>Wednesday 01.06.2022 16.35-16.45</td>
<td>Plenary Abstract Session</td>
<td>Caillet-Portillo, D (France)</td>
<td>IMPACT OF DIAGNOSIS AND TREATMENT OF TROPHERYMA WHIPPLEI INFECTION IN PATIENTS WITH PRE-EXISTING CHRONIC INFLAMMATORY RHEUMATIC DISEASES: DATA FROM THE NATIONAL TW-IRD REGISTRY</td>
</tr>
<tr>
<td>Oral 0043</td>
<td>Wednesday 01.06.2022 16.45-16.55</td>
<td>Infection-related and other orphan rheumatic disorders</td>
<td>Henes, J (Germany)</td>
<td>TOCILIZUMAB SIGNIFICANTLY REDUCES SERUM AMYLOID A IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER – DATA FROM THE PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TOFFIFE STUDY</td>
</tr>
<tr>
<td>Oral 0047</td>
<td>Wednesday 01.06.2022 17.15-17.25</td>
<td>Infection-related and other orphan rheumatic disorders</td>
<td>Demrici-Yildirim, T (Turkey)</td>
<td>IMPAIRED JAK-STAT PATHWAY IN PATIENTS WITH PYODERMA GANGRENNOSUM</td>
</tr>
<tr>
<td>Oral 0049</td>
<td>Wednesday 01.06.2022 17.35-17.45</td>
<td>Infection-related and other orphan rheumatic disorders</td>
<td>Terrier, B (France)</td>
<td>FURTHER CHARACTERIZATION OF CLINICAL AND LABORATORY FEATURES OCCURRING IN VEXAS SYNDROME IN A LARGE-SCALE ANALYSIS OF MULTICENTER CASE-SERIES OF 116 FRENCH PATIENTS</td>
</tr>
<tr>
<td>Oral 0045</td>
<td>Wednesday 01.06.2022 17.45-17.55</td>
<td>Infection-related and other orphan rheumatic disorders</td>
<td>MYACHIKOVA, V (RUSSIA)</td>
<td>TREATMENT OF IDIOPATHIC RECURRENT PERICARDITIS WITH GOFLIKICEPT - FIRST DATA FROM THE INTERIM ANALYSIS OF PHASE 2/3 ONGOING STUDY</td>
</tr>
</tbody>
</table>

This interim analysis showed that 63% of FMF patients were in remission status at month 24 with canakinumab.

This registry aimed to describe the characteristics of inflammatory rheumatic disorders (IRD) with concomitant *Tropheryma whippelii* (Tw) infections. Tw infection treatment was associated with IRD remission in 93% of cases.

In this first randomized, placebo-controlled study in patients with active colchicine resistant FMF Tocilizumab significantly reduced and normalized SAA levels.

This study showed that JAK1 was overexpressed in Pyoderma versus Psoriasis in cytoplasmic parts of the epidermis. TYK2 and STAT6 were highly expressed in the Psoriasis versus Pyoderma in cytoplasmic parts of the epidermis.

This study showed that patients with UBA1 p.Met41Leu mutation was associated with a better prognosis whereas patients with underlying MDS had higher mortality rates.

In this randomized controlled study, recurrent pericarditis occurred in 8 of 10 patients in placebo group whereas there were no recurrence events in goflikicept group to the moment of this interim analysis.
Silvia Piantoni is a Post-Doctoral Research Fellow and Consultant in Rheumatology at the University Hospital in Brescia (Italy). During her PhD Course in Immunology, she moved to Geneva for a lab-based research project. Her translational research focuses on the involvement of T lymphocytes in autoimmune diseases. Silvia is the Chair of the eular | EMEUNET Peer Review Mentoring Subcommittee.

### IMAGING

Silvia Piantoni

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0864</td>
<td>Wednesday 01 June 2022 17:28 - 17:36</td>
<td>Scleroderma, myositis and related syndromes</td>
<td>C. Bergmann (Germany)</td>
<td>ASSESSMENT OF SYSTEMIC SCLEROSIS RELATED MYOCARDIAL FIBROSIS BY 68GA-FAPI-04 PET/CT</td>
</tr>
</tbody>
</table>

This is the first evidence on a limited number of patients that Fibroblast-Activation-Protein (FAP) - based PET correlates with fibrotic activity in SSc-associated myocardial fibrosis.

| Oral 0026 | Wednesday 01 June 2022 17:45 - 17:55 | Clinical aspects in Psoriatic Arthritis | Kading, H (Germany) | CLINICAL AND IMAGING-BASED CHARACTERIZATION OF A PROSPECTIVE COHORT OF PATIENTS WITH AXIAL PSORIATIC ARTHRITIS (AXIAL PSA). GESPIC - AXIAL PSA: RESULTS OF AN INTERIM ANALYSIS |

Imaging-defined axial PsA patients showed peculiar features when compared with the described cohort of “classical” axial SpA. They are more frequently female without positivity for HLA-B27.

| Poster 0782 | Wednesday 01 June 2022 19:52 - 20:00 | SLE, Sjögren’s and APS - clinical aspects (other than treatment) | Galisteo, C (Spain) | ULTRASONOGRAPHIC EVALUATION OF MAJOR SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME: COMPARISON OF THREE SCORING SYSTEMS AND ASSOCIATION WITH BIOPSY RESULTS |

Currently, SGUS cannot replace the biopsy for diagnosis purposes in patients with primary Sjögren’s syndrome.

| Oral 0288 | Friday 03 June 2022 10:45 - 10:55 | The early bird gets the worm | Molina Collada, J (Spain) | IMPACT OF CARDIOVASCULAR RISK ON THE DIAGNOSTIC ACCURACY OF THE ULTRASOUND HALO SCORE FOR GIANT CELL ARTERITIS |

CVR should be taken into consideration in the US vascular assessment of patients with suspected GCA because it may influence the diagnostic accuracy of the US Halo Score.

| Oral 0292 | Friday 03 June 2022 11:25 - 11:35 | The early bird gets the worm | Folle, L (Germany) | CLASSIFICATION OF PSORIATIC ARTHRITIS, SERONEGATIVE RHEUMATOID ARTHRITIS, AND SEROPOSITIVE RHEUMATOID ARTHRITIS USING DEEP LEARNING ON MAGNETIC RESONANCE IMAGING |

Deep learning using neural networks on MRI can be applied to differentiate inflammatory patterns related to RA+, RA-, and PsA.

| Poster 0273 | Saturday 04 June 11:13 - 11:21 | Achy-Breaky vessels | Martinho, J (Portugal) | THE ROLE OF FACIAL, OCCIPITAL, SUBCLAVIAN AND CAROTID ARTERIES ULTRASOUND IN THE DIAGNOSTIC ASSESSMENT OF GIANT CELL ARTERITIS |

This study supports the need to US assess temporal, axillary and subclavian arteries in patients with suspected GCA, resulting in a diagnostic sensitivity of 100%.
PAEDIATRIC RHEUMATOLOGY
Lovro Lamot

- Lovro is paediatric rheumatologist, paediatric nephrology fellow and postdoctoral fellow at Department of Paediatrics, University Hospital centre Zagreb and University of Zagreb School of Medicine in Zagreb, Croatia. His research interest include biomarkers of immune mediated inflammatory diseases in children. Lovro is the head of EMERGE group of young pediatric rheumatologists and researchers, trainee representative in PRES council and member of EULAR Paediatric Rheumatology Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0164</td>
<td>Friday 03.06.2022 12.02 – 12.10</td>
<td>Improving our care and understanding of paediatric RMDs</td>
<td>Tordoff, M (UK)</td>
<td>GENETIC ANALYSIS OF WHOLE EXOME SEQUENCING IN A COHORT OF CHILDREN WITH REFRACTORY JIA REVEALS GENETIC RISK FACTORS FOR RARE JUVENILE DISEASES</td>
</tr>
<tr>
<td>Poster 0166</td>
<td>Friday 03.06.2022 12.10 – 12.18</td>
<td>Improving our care and understanding of paediatric RMDs</td>
<td>Sag, E (Turkey)</td>
<td>POLYARTICULAR JIA HAS A DISTINCT CO-INHIBITOR RECEPTOR PROFILE AMONG OTHER JIA SUBTYPES</td>
</tr>
<tr>
<td>Poster 0168</td>
<td>Friday 03.06.2022 12.26 – 12.34</td>
<td>Improving our care and understanding of paediatric RMDs</td>
<td>Pain, C (UK)</td>
<td>NON-INVASIVE IMAGING IN JUVENILE LOCALISED SCLERODERMA: HIGH-FREQUENCY ULTRASOUND, THERMOGRAPHY, LASER DOPPLER &amp; MULTISPECTRAL IMAGING</td>
</tr>
<tr>
<td>Poster 0342</td>
<td>Saturday 04.06.2022 11.05 – 11.13</td>
<td>New insights into the management of JIA</td>
<td>Arkachaisri, T (Singapore)</td>
<td>ANTI-TUMOUR NECROSIS FACTOR (ATNF) WEANING STRATEGY IN JUVENILE IDIOPATHIC ARTHRITIS (JIA): DOES LONGER DURATION MATTER?</td>
</tr>
<tr>
<td>Poster 0337</td>
<td>Saturday 04.06.2022 11.21 – 11.29</td>
<td>New insights into the management of JIA</td>
<td>Shoop-Worrall, S (UK)</td>
<td>DISTINCT CLUSTERS OF JIA AT METHOTREXATE INITIATION IDENTIFIED USING TOPOLOGICAL DATA ANALYSIS</td>
</tr>
<tr>
<td>Poster 0341</td>
<td>Saturday 04.06.2022 11.29 – 11.37</td>
<td>New insights into the management of JIA</td>
<td>Weiss, PF (USA)</td>
<td>CONSENSUS-DRIVEN DEFINITION FOR UNEQUIVOCAL SACROILIITIS ON RADIOGRAPHS IN JUVENILE SPONDYLOARTHRITIS</td>
</tr>
</tbody>
</table>

The study highlighted a genetic basis for refractory juvenile idiopathic arthritis.

The first study reporting the effects of different co-inhibitory receptors in different subtypes of juvenile idiopathic arthritis.

The study suggested non-invasive imaging can detect differences between healthy & unaffected skin in juvenile localized scleroderma.

The study showed that duration of spacing out the aTNF therapy after achieving remission on medications may not minimize the flare rate or delay time to flare after stopping the therapy in juvenile idiopathic arthritis patients.

The study showed substantial heterogeneity in juvenile idiopathic arthritis patients at the point of methotrexate initiation.

The study proposed a consensus-derived definition of unequivocal sacroiliitis by radiography in skeletally immature children and adolescents.
Alessandro is a PhD and rheumatologist at the Division of Rheumatology, University Hospital of Padua, Italy. His major research interests include refractory rheumatoid arthritis, vasculitides and systemic sclerosis with special focus on cardiovascular outcomes. Alessandro is a member of the Country Liaison Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 0250</td>
<td>Friday, 03.06.2022 11:05 – 11:15</td>
<td>Outcome of COVID-19 in Rheumatic Diseases</td>
<td>Yusof, M. Y. Md. (UK)</td>
<td>BREAKTHROUGH INFECTIONS AND PREDICTING SEVERE COVID OUTCOMES DURING RITUXIMAB THERAPY IN AUTOIMMUNE RHEUMATIC DISEASES</td>
</tr>
<tr>
<td>Oral 0252</td>
<td>Friday, 03.06.2022 11:25 – 11:35</td>
<td>Outcome of COVID-19 in Rheumatic Diseases</td>
<td>Yeoh, S. A. (UK)</td>
<td>FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY</td>
</tr>
<tr>
<td>Oral 0175</td>
<td>Thursday 02.06.2022 11:05 – 11:15</td>
<td>Vaccination against SARS-CoV2-2</td>
<td>Raptis, C. E (Switzerland)</td>
<td>TYPE OF mRNA COVID-19 VACCINE AND TREATMENT INFLUENCE ANTIBODY KINETICS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES</td>
</tr>
<tr>
<td>Poster 0195</td>
<td>Friday 03.06.2022 12:10 – 12:18</td>
<td>Outcome of COVID-19 in patients with rheumatic diseases</td>
<td>Bruera S. (USA)</td>
<td>PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS HAVE AN INCREASED RISK OF MORTALITY, MECHANICAL VENTILATION, AND HOSPITALIZATION FROM COVID-19</td>
</tr>
</tbody>
</table>

This global registry data inform on the impact of COVID-19 on myositis patients. There were no additional signals of concern among patients with myositis than those already been associated with worse COVID-19 outcomes in rheumatic patients.

This study shows different anti-SARS-CoV-2 IgG titres in response to mRNA-1273 compared to BNT162b2 vaccines among individuals with inflammatory rheumatic diseases.

COVID-19 related risks of mortality, mechanical ventilation, and hospitalization within 30 days were increased in individuals with systemic lupus erythematosus compared to matched controls.

This joint rheumatology-psychiatry study highlights the high prevalence of symptomatic post-traumatic stress disorder among patients with rheumatic musculoskeletal diseases during the COVID-19 pandemic.

The incidence of COVID-19 hospitalisation was increased for both unvaccinated and vaccinated patients with RA compared with controls, but authors also found a signal for decreasing risk for patients with RA thanks to vaccination.
Peter is the incoming Chair-elect of the PARE Committee. Peter has volunteered for PARE for a number of years while volunteering for his national organisation Arthritis Ireland. Peter has advocated on behalf of patients with a particular emphasis on employment rights and improved patient/doctor communication.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Wednesday, 01.06.2022 15.03 – 15.13</td>
<td>How to maintain your quality of life after an RMD diagnosis</td>
<td>Petra Borsje (Netherlands)</td>
<td>DEVELOPMENT OF CONVERSATION AIDS: HOW TO GET THE MOST OUT OF YOUR RMD APPOINTMENT AND ADVANCE YOUR QUALITY OF LIFE.</td>
</tr>
<tr>
<td>Oral</td>
<td>Wednesday, 01.06.2022 16.58 – 17.08</td>
<td>In dialogue with the expert: axSpA and Sjögren's syndrome</td>
<td>Olga Krichevskaya (Russia)</td>
<td>THE WEBINAR SERIES FOR THE PATIENTS &quot;PREGNANCY AFTER DIAGNOSING ANKYLOSIS SPONDYLITIS&quot;</td>
</tr>
<tr>
<td>Oral</td>
<td>Friday 03.06.2022 10.55 – 11.05</td>
<td>From abstract to concrete – the variety of activities of PARE organizations</td>
<td>Nienke Bakker (Netherlands)</td>
<td>DEVELOPMENT THROUGH CO-CREATION OF A PERSONALIZED, MULTIMODAL, PHYSIOTHERAPIST-LED, WORK-ORIENTED INTERVENTION TO INCREASE WORK ABILITY IN WORKING PEOPLE WITH RHEUMATOID ARTHRITIS OR AXIAL SPONDYLOARTHRITIS.</td>
</tr>
<tr>
<td>Oral</td>
<td>Friday 03.06.2022 16.33 – 16.43</td>
<td>Enhancing research through patient involvement</td>
<td>Monica Persson (Sweden)</td>
<td>EXPERIENCES AND IMPACT OF PATIENT AND PUBLIC INVOLVEMENT IN SWEDISH RHEUMATOLOGY RESEARCH: A SURVEY OF RESEARCHERS AND PATIENT RESEARCH PARTNERS</td>
</tr>
</tbody>
</table>

All patients want to make sure that research is inclusive of their experiences and knowledge. It is important to evaluate how successful patient and public involvement (PPI) is and how impactful it is.
**HEALTH PROFESSIONALS IN RHEUMATOLOGY**

**Thomas Davergne**

* Thomas Davergne is a French physiotherapist specialising in inflammatory arthritis and has a PhD in epidemiology. His main research interests are strategies to improve physical activity levels in rheumatology, digital tools and barriers and facilitators to physical activity.

He also teaches evidence-based medicine at Masters and physiotherapy schools.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 0120</td>
<td>Thursday 02.06.2022 11:15 - 11:25</td>
<td>HPR: From prevention to management</td>
<td>Sigaux, J (France)</td>
<td>IMPACT OF DIFFERENT TYPES OF PHYSICAL ACTIVITY PROGRAMS ON ANKYLOSING SPONDYLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
</tr>
</tbody>
</table>

This review shows the most effective types of physical activity for spondyloarthritis.

| Oral 0296 | Friday 03.06.2022 16:50 - 17:00 | Complexity of care in RMD: intersection between health and social care | Feddersen, H (Denmark) | HEALTH AND SOCIAL CARE PROFESSIONALS’ WORK TO ACHIEVE COHERENT REHABILITATION PATHWAYS FOR PEOPLE WITH INFLAMMATORY ARTHRITIS - A QUALITATIVE INTERVIEW AND OBSERVATIONAL STUDY |

This qualitative study exposes the gap between the willingness of caregivers to propose a patient-centred approach and the reality of care underpinned by organisational constraints and collaboration between health professionals.

| Oral 0007 | Wednesday 01.06.2022 17:35 - 17:45 | "Not another pill!" Integrative pain management approaches | Jobanputra, D (UK) | AN EPIDEMIOLOGICAL STUDY OF FOOT AND ANKLE PAIN AND HEALTH-RELATED JOB LOSS IN ADULTS OVER 50: CROSS-SECTIONAL FINDINGS FROM THE HEAF COHORT |

This cohort explores the consequences of foot and ankle pain on work activity, and specifically health-related job loss.

| Oral 0198 | Thursday 02.06.2022 18:35 - 18:45 | How do we overcome the research-to-practice gap? Implementation of evidence into the rheumatology practice | Primdahl, J (Denmark) | DEVELOPMENT OF AN INTERDISCIPLINARY NURSE-COORDINATED SELF-MANAGEMENT INTERVENTION (INSELMA) FOR PATIENTS WITH INFLAMMATORY ARTHRITIS |

This study describes the development and preliminary results of a promising interdisciplinary self-management intervention coordinated by a nurse, following the British Medical Research Councils framework for the development of Complex Interventions.

| Oral 0301 | Saturday 04.06.2022 10:05 - 10:15 | Digital-Health and Tailored Interventions for Improving Patients’ Adherence: Opportunities and Challenges | Van Lierde, C (Belgium) | PATIENT ADHERENCE TO E-HEALTH INTERVENTIONS FOR REMOTE DISEASE MONITORING IN CHRONIC ARTHRITIS |

This systematic review explores characteristics associated with greater adherence to e-health tools for remote monitoring of symptoms or disease activity in chronic arthritis.

| Poster 0045 | Thursday 02.06.2022 12:34 - 12:42 | Poster Tour Auditorium 2 | Kvernberg Thomassen, E (Norway) | HEALTHCARE PROFESSIONALS’ ATTITUDE TOWARDS REMOTE MONITORING |

This survey explore healthcare professionals’ attitude, facilitators and barriers on use of remote monitoring in a specialist healthcare setting.
EULAR 2022 will be an extraordinary year for EULAR, marking not only our first-ever hybrid congress but also our 75th anniversary! We look forward to welcoming you on-site in Copenhagen or virtually. Read the welcome message from the EULAR President, Prof. Annamaria Iagnocco.

The EULAR 2022 Scientific Programme is now online!

The EULAR 2022 Scientific Programme will start on Wednesday, 1 June 2022

Go to programme

EULAR 2022 Congress will be held both virtually and onsite in Copenhagen, offering our first-ever hybrid congress experience.

Registration is now open!

EULAR 2022 Congress
June 1-4, 2022
Join us in Copenhagen or online
EMEUNET PRESENTS

For several years, EMEUNET working group members (now subcommittee members) have had the opportunity to propose educational sessions at EULAR. These sessions have now been rebranded as "EMEUNET Presents". Don’t miss them!

Wednesday
01.06.2022
14:15 - 15:30
Auditorium 10

Social Media and Digital Sources in Rheumatology

Chairs: Prof. Loreto Carmona, Ertugrul Cagri Bolek

Prof. Laurent Arnaud. Being a twitter influencer for education and awareness in rheumatology

Dr. Michael Putman. Keeping up with podcasts as an educational and academic tool

Dr. Simon Stones. Raising the voice of patients with RMD in social media

Thursday
02.06.2022
13:30 - 14:45
Auditorium 10

Involved, Insightful, Invaluable: The Impact of Patient and Public Involvement in Research

Chairs: Dr. Mrinalini Dey, Mr. Peter Boyd

Dr. Ricardo J. O. Ferreira. Citizen Involvement in Research: The Role of the Multidisciplinary Team

Ms. Codruta Zabalan. Research in RMDs: A Personal Perspective

Dr. Alessia Alunno. Young People with RMDs and Rheumatology Research: A Story of Success

Friday
03.06.2021
15:45 – 17:00
Auditorium 10

Applications and motivation – separating the good from the excellent

Chairs: PhD Manouk de Hooge, Prof. Rik Lories

Prof. Laure Gossec. What to do / what not to do?

Prof. Pedro M Machado. How to write a motivational section that stands out

Prof. Dr. Lars Klareskog. Tips and tricks when submitting a grant

Saturday
04.06.2021
12:00 – 13:15
Auditorium 10

How to review a manuscript

Chairs: MD, PhD Silvia Piantoni, Prof. Dr. Bernard Combe

Dr. Chiara Crotti. Which are the pitfalls in reviewing a manuscript? The young point of view.

Prof. Dr. Axel Finckh. Which are the pitfalls in reviewing a manuscript? The senior point of view.

Prof. Joao Eurico Fonseca. The future of reviewing. Do we need a specific training?

Dr. L.M. Verhoef. OP0305 The Emerging EULAR Network (EMEUNET) Peer-Review Mentoring Program: Ten years of Initiative.
As in previous years, and after two years of virtual meetings, the EMEUNET Country Liaison Meeting will take place on-site during the EULAR Congress!

We will have the opportunity to hear some of our Country Liaisons presentations on their activities during last year and we will have time for discussion and brainstorming for next year’s new projects.

This meeting is the best opportunity for the Country Liaisons to share their ideas with the subcommittee members and to pose any challenges they face when promoting our network to ultimately shape the upcoming initiatives.

The 9th EMEUNET Country Liaison Meeting will take place on

Friday 3rd June at 16.30h (CEST)

The definite agenda will be sent in the next few days.
We invite all the Country Liaisons to check the email and to confirm their attendance.

The EMEUNET Country Liaison Subcommittee

Pictures from Country Liaison meetings held in the last 4 years.
The EMEUNET Research Speed-Dating is an organized networking activity during the EULAR 2022 conference in which young rheumatologists and researchers interact in a series of short one-on-one conversations to determine if there is mutual interest for research collaborations. The EMEUNET research Speed-Dating will provide an opportunity for participants to explore collaboration interests in a cursory way, forming the basis for further and more profound interaction.

**Location:** EULAR 2022 Congress Venue

**Time & Date:** Thursday 2nd of June at 12 pm

For more information, access through the [EULAR website](#).
Would you like to discuss research topics and career plans in an informal atmosphere with an expert in your field? The Mentor-Mentee meetings are a ‘do not miss’ opportunity for you!

EULAR 2022 (18th edition) – Congress Venue – THURSDAY 2nd of June

**GROUP 1  BASIC SCIENCE**

Prof. Peter Lamprecht

Full Professor and Consultant
Department of Rheumatology and Clinical Immunology,
Deputy Director
Comprehensive Center of Inflammation Medicine (CCIM),
University Medical Center of the State of Schleswig-Holstein (UKSH),
University of Lübeck

Lübeck, Germany

Keywords: basic and translational research, granulomatosis with polyangiitis, vasculitis, chronic inflammation, T cells, precision medicine

**GROUP 2 CLINICAL SCIENCE**

Prof. Laura Coates

Associate Professor and Honorary Consultant Rheumatologist
University of Oxford in the UK, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
Member of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Oxford, United Kingdom

Keywords: clinical research, psoriatic arthritis, inflammatory arthritis, early diagnosis, outcome measures, clinical trials

**INTERESTED?** Send your application with a snapshot and your preferred group to: mentoring.emeunet@gmail.com
Dear EMEUNET members,

We would like to invite you to participate in the inaugural edition of the “EULAR/EMEUNET Interest groups” during the virtual EULAR Congress 2022.

Interest Groups are a virtual initiative with the aim to offer networking space for the researchers/clinicians interested in a specific topic. In each group we will offer 1) a live chat forum to virtually interact during the whole congress and 2) participation in a live video interactive discussion with the rest of the group and an invited speaker.

This is a unique opportunity to meet and interact with colleagues from the field and discuss hot topics during the EULAR 2022 Congress.

The Interest groups in the virtual platform, in the “Networking” part of the platform.

You will find the complete programme of the seven Interest Groups down below, we hope you will find them of interest!
EULAR/EMEUNET INTEREST GROUPS
DURING THE EULAR CONGRESS 2022

GROUP 1
Basic Research
Thursday
June 2nd
09.30 – 10.30
CEST

Ambassador: Blaž Burja

Title: Cross-tissue targeting of pathogenic fibroblast subsets: where do we stand?

Invited Speaker: Prof. Buckley

The traditional view of fibroblasts as the structural only framework of human tissue has changed considerably by discovering their active roles in shaping tissue microenvironment in health and disease. Pathogenic fibroblasts represent key drivers of chronic inflammation, fibrosis and tissue damage; fibroblast-targeting strategies, however, remain scarce. The era of new technologies, such as single-cell transcriptomics, revolutionised our understanding of intra-tissue fibroblast heterogeneity. Unravelling the composition and function of different fibroblasts subpopulations in homeostasis and disease will pave the way toward therapeutic targeting of fibroblasts in autoimmune diseases and beyond. With Prof. Christopher Buckley we will address the role of pathogenic fibroblast subtypes across different tissues and provide the rationale for developing fibroblast-targeting therapeutics.

GROUP 2
Rheumatoid arthritis
Thursday
June 2nd
14:45 – 15:45
CEST

Ambassador: Lise Verhoef

Title: Decision-support in RA treatment: when do prediction and machine learning make sense?

Invited Speaker: Dr Paco Welsing

The RA interest group will focus on decision-support using prediction through traditional statistical methods and machine learning approaches. We will talk about the basic concepts of prediction research, machine learning and the opportunities and challenges for implementation in clinical care. Dr. Paco Welsing will tell us more about the development and testing of a tool to predict RA flares during tapering of biologicals. The PATIO study, currently being executed in the Netherlands, is one of the few clinical trials in which the impact of using such a prediction tool is compared to usual care. There will be room for questions, discussion and input from the audience. We hope to see you there!

GROUP 3
Spondyloarthritis/PsA
Friday
June 3rd
14.45 – 15:45
CEST

Ambassador: Fabian Proft

Title: Axial involvement in PsA (axPsA) compared with axial SpA: is it same or different?

Invited Speaker: Prof. Dafna Gladman

Psoriatic Arthritis (PsA) is a chronic inflammatory disease that can be subsumed together with axial spondyloarthritis (axSpA) under the umbrella term spondyloarthritis (SpA). About one third of PsA patients are described to suffer from an axial manifestation, but it is still a matter of debate whether they belong to one spectrum of the same disease with different phenotypes or should be considered as separate diseases with frequent similarities. We are glad to have Professor Dafna Gladman as one of the leading PsA experts with us to discuss recent advantages in the understanding of axial PsA, to deliberate the scientific contributions at this year’s EULAR regarding axial PsA, brainstorm on the research agenda of this ‘hot topic’ and take a look into the future in terms of diagnosis, classification and treatment of this specific entity.
Despite recent advances, many clinical and scientific questions remain open about primary Sjögren’s syndrome (pSS). There are no specific diagnostic tests for the disease. Over the last 3 decades, several sets of classification criteria have been developed, culminating in the recent ACR-EULAR classification criteria. The epidemiology of pSS is overall poorly defined, but several recent reports worldwide contributed to a better understanding of its incidence and prevalence, demonstrating that pSS is a rare disease. The evaluation of disease activity and course is difficult, mainly due to the subjective and variable nature of its symptoms, and to the rarity and heterogeneity of the systemic manifestations. A strong global research effort is currently being developed in that field and new tools are being developed. Biological abnormalities associated with B lymphocytes are a hallmark of patients with pSS, but until now no B-cell targeting strategy has proven its efficacy in the disease. However, recent clinical trials demonstrated encouraging results, leading to ongoing large phase 3 trials of drugs specifically developed for the disease.

IgG4-RD remains a diagnostic challenge to clinicians since its several kinds of presentations, lack of definitive diagnostic serum biomarkers or imaging tests, and substantial overlap with its various mimickers. Despite these challenges, rheumatologists should seek a better understanding of IgG4-RD while an early diagnosis and treatment can prevent disease complications. In this session, we will discuss diagnostic challenges and the implementation of the 2019 ACR/EULAR Classification Criteria in daily practice with Prof. John H. Stone who is one of the most influential IgG4-RD experts.

The Epidemiology interest group will focus on difficult-to-treat arthritis, with our keynote speaker, Prof Jaap Van Laar. This is following the recent publication of the EULAR definition and guidance on this. This discussion will complement the “How To Treat” session on this topic, which will also feature Prof Van Laar as the main speaker. Participants will have the opportunity to hear more about his work and career, discuss the fascinating area of difficult-to-treat arthritis, and discuss Prof Van Laar’s extensive contribution to rheumatology more broadly.
Many of us see the potential for using PROs in daily practice, but this has not been thoroughly investigated yet. Since PROs reflect the patients’ wellbeing, it could play a role in the outpatient clinic in improving patient journeys. Possibly, use of PROs can improve shared-decision making between the rheumatologist and the patient. In this session, we will discuss challenges and opportunities with dr. Annelieke Pasma, who is an expert in the field of shared decision making in rheumatology.
EULAR has developed e-learning opportunities with the newest updates in the field of rheumatology. 99 modules are available, covering different areas of rheumatology.

- **Fee:** 25 EUR for each module
- **Start:** no deadline / any time
- **Available for:** 1 year after booking

---

**11th EULAR Online Introductory Ultrasound Course**

The course, covering 7 modules, is designed for approx. 7 months of training, the expected learning time per week is around 2 1/2 hours. Upon passing the examination, a EULAR certificate will be issued.

- **Fee:** 150 EUR
- **Start:** 17.10.2022; **Registration will open in June 2022**
- **Available for:** 1 year + 1 year extension

---

**12th EULAR Online Course on Systemic Sclerosis**

The Course consists of 10 modules dealing with physiopathology, clinical aspects and management of SS. All modules are developed by EUSTAR.

- **Fee:** 150 EUR
- **Start:** 17.10.2022; **Registration will open in June 2022**
- **Available for:** 1 year + 1 year extension

---

**17th EULAR Online Course on Rheumatic Diseases**

The course is managed by a scientific course committee controlling the structure and content of the course and performing regular quality control and advancement. The full version covers the entire field of rheumatology and consists of 55 illustrated modules (of which some are optional), each one covering a specific topic. The expected learning time per week is calculated around 2 1/2 hours but very flexible for the learners who can enter the learning system at any time and have available free of charge an extra year if needed.

Knowledge and skills are targeted to suit a level of knowledge appropriate for the final years of training as a rheumatologist.

- **Fee:** 150 EUR
- **Start:** 17.10.2022; **Registration will open in June 2022**
- **Available for:** 2 years + 1 year extension
EULAR ONLINE COURSES AND MODULES

14th EULAR Online Course on Connective Tissue Diseases
The Course consists of 16 modules which deal with immunology and systemic auto-immune diseases, such as SLE, scleroderma, and vasculitis.
➢ Fee: 150 EUR
➢ Start: 17.10.2022; Registration will open in June 2022
➢ Available for: 1 year + 1 year extension

2nd EULAR Online Course on Patient Education for Physicians and Health Professionals
The Course consists of 4 modules (approx. 6 hours each). The learning objectives are: understand the problematics of chronic rheumatic diseases, understand issues of patient education, develop attitudes in the relationship with the patient, elaborate a program of patient education, perform an educational diagnosis, design and animate educational workshops evaluate a program and among different learning objectives. Upon passing the examination a EULAR certificate will be issued.
➢ Fee: 150 EUR
➢ Start: 17.10.2022; Registration will open in June 2022
➢ Available for: 1 year + 1 year extension

4th EULAR Online Course for Systemic Lupus Erythematosus
The Course consists of 12 modules covering the recent updates in diagnosing and managing SLE, as well as the recent updates to management guidelines.
➢ Fee: 150 EUR
➢ Start: 17.10.2022; Registration will open in June 2022
➢ Available for: 1 year + 1 year extension

5th EULAR Online Course on Imaging in RMDs
The Course covers 3 modules. The learner level is aimed primarily at Section Residents and Fellows in Training as well as Rheumatologists. It aims to educate rheumatologists and future rheumatologists on how to interpret imaging examinations in chronic inflammatory RMDs and to use the imaging results to guide their daily treatment.
➢ Fee: 150 EUR
➢ Start: 17.10.2022; Registration will open in June 2022
➢ Available for: 1 year + 1 year extension
EULAR ONLINE COURSES AND MODULES

8th EULAR Online Course for Health Professionals in Rheumatology
The course consists of a total of 8 modules. Care is given to integrate the multidisciplinary perspective of the treatment of rheumatic diseases.
- **Fee**: 150 EUR
- **Start**: 17.10.2022; **Registration will open in June 2022**
- **Available for**: 1 year + 1 year extension

9th EULAR/PRES Online Course in Paediatric Rheumatology
The 11-module course represents a joint effort of EULAR and the Paediatric Rheumatology European Society (PRES), offering a deep insight of all the aspects related to rheumatic diseases in children and adolescents including their impact on the growing body and the differential diagnosis with other paediatric disorders.
- **Fee**: 150 EUR
- **Start**: 17.10.2022; **Registration will open in June 2022**
- **Available for**: 1 year + 1 year extension
UPCOMING EDUCATIONAL EVENTS

JUNE 2022

**EULAR 2022**
- When and Where: 1-4 Jun 2022, Copenhagen- Hybrid Event
- Website: [https://congress.eular.org/index.cfm](https://congress.eular.org/index.cfm)

**European Society of Musculoskeletal Radiology (ESSR) Congress 2021**
- When and Where: 9-11 Jun 2022, Rostock/Germany
- Website: [https://www.essr.org/congress/essr-2022/](https://www.essr.org/congress/essr-2022/)

**Federation of Clinical Immunology Societies (FoCIS) Annual Meeting 2021**
- When and Where: 21-24 Jun 2022, San Francisco, CA USA
- Website: [https://www.focisnet.org/meetings/focis-2022/](https://www.focisnet.org/meetings/focis-2022/)

JULY 2022

**16th World Immune Regulation Meeting**
- When and Where: 6-9 Jul 2022, Davos, Switzerland
- Website: [http://www.wirm.ch/](http://www.wirm.ch/)

**Ten Topics in Rheumatology**
- When and Where: 07-08 Jul 2022, Hilton Tower Bridge Hotel, London
- Website: [http://tentopics.com/](http://tentopics.com/)

**2nd PAFLAR Congress**
- When and Where: 29 Jun- 1 Jul 2022, Virtual Event
- Website: [https://paflar.org/2022-paflar-congress/](https://paflar.org/2022-paflar-congress/)
By 2023, EULAR will be the leading provider of education in rheumatic and musculoskeletal diseases (RMDs).

**EULAR School of Rheumatology**

**EULAR Online courses:**
- RMD: EULAR Course on Rheumatic Diseases
- US: EULAR Online Introductory Ultrasound Course
- IMG: EULAR Online Course on Imaging in RMDs
- PAED: EULAR / PRES Online Course in Paediatric Rheumatology
- HPR: EULAR Online Course for Health Professionals in Rheumatology
- SSc: EULAR Online Course on Systemic Sclerosis

**The EULAR Educational Cooperation with National Societies (EULAR ECONS)**
The EULAR Research Consultation Service

How does it work?

1. Select your support area and describe your needs in a short online form
2. Get matched with an experienced scientist
3. Obtain up to 10 hours of free consultation
4. Share your feedback upon service completion

Support Areas

- Basic/Translational Research (using patient/human materials, e.g. cells, serum...or Dedicated animal models of RMDs to address bedside-to-bench research questions)
- Clinical Research
- Epidemiology and Public Health
- Health Services Research
- Implementation Science

The EULAR Research Consultation Service is offered through the EULAR Research Centre. The service is available for researchers based in EULAR-affiliated countries.
EULAR OUTCOME MEASURES LIBRARY (OML)

The EULAR Outcome Measures Library (OML) aims to be a comprehensive database of validated instruments (indices, questionnaires, scales, or others), with an emphasis on patient-reported outcomes (PRO) used in rheumatology. The EULAR OML was created by rheumatologists, health professionals, students and patients, all of whom are engaged in the field of rheumatology. The database includes a detailed description of each instrument, including the instrument itself (and validated language versions, if available), useful references, a description of the population(s)/setting(s) where it has been validated, recommendations and rules for use, guideline for interpretation of the results in clinical practice or in research, information on the most relevant psychometric properties of each instrument. Instruments are categorized by disease or by topic. Also, guidelines for interpretation of results in both practice and research settings are provided. The OML is an ongoing project and is frequently updated with the most recent information on PROs in rheumatology.

For more information visit:
http://oml.eular.org/
The European Alliance of Associations for Rheumatology (EULAR) is very concerned about the situation in Ukraine, and it condemns Russia's unacceptable act of aggression towards the country. As hospitals are being attacked and access to medical aid is interrupted, EULAR wants to respond to this humanitarian crisis and particularly support the Ukrainian people with rheumatic and musculoskeletal diseases (RMDs), who need urgent treatment and assistance.

Together with EMEUNET, EULAR has developed a support programme for young Ukrainian rheumatologists, enabling them to take up their profession, maintain and further develop their skills, and provide care to a range of patients, including particularly displaced Ukrainian RMD patients. Across Europe, Ukrainian rheumatologists or rheumatologists in training can apply for this programme, sponsoring their employment in one of EULAR's various partner hospitals or institutes. EULAR will fund up to 20 such positions, allowing for a stable income for a Ukrainian physician who had to flee their country, and securing medical treatment for Ukrainian refugees with RMDs. EULAR will provide €500,000 for this purpose.

What: Funding programme for displaced Ukrainian physicians
Who can apply: Hospitals or medical institutions (employers) in countries with many displaced Ukrainian refugees
Target group: Ukrainian rheumatologists, focus on rheumatologists in training
How much: 20.000 – 30.000 EUR/year

Please send your application to eular@eular.org.
SHARE YOUR IDEAS!

Over the years EMEUNET has developed several projects covering different topics and areas of interest. However, we always appreciate any suggestions and welcome new ideas to expand on what we currently offer to EMEUNET members. Make your voice heard and share your ideas with us!

For additional suggestions and ideas, just write down some lines to summarize your proposal and send it either via email at emeunet@eular.ch or through our website (http://emeunet.eular.org/contact_us.cfm). Don’t forget to provide your contacts so we can come back to you for additional details!

More information about EMEUNET can be found at http://emeunet.eular.org

www.facebook.com/EMEUNET
www.twitter.com/EMEUNET
https://www.linkedin.com
EMEUNET Tube
EMEUNET Podcast
EMEUNET Instagram